Coronavirus infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:14:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Coronavirus infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Immune Response of OVX033 Vaccine for Adults with Sarbecovirus Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-ovx033-vaccine-for-adults-with-sarbecovirus-disease/ Wed, 29 Apr 2026 15:05:50 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-ovx033-vaccine-for-adults-with-sarbecovirus-disease/ This clinical trial is focused on studying a disease caused by , which are a group of viruses that include the virus responsible for COVID-19. The study is testing a new vaccine called , which is given as a solution for injection. The vaccine is being compared to a placebo to see how safe it is and how well it works in helping the body fight off the virus.

The purpose of the study is to evaluate the safety and immune response of the vaccine. Participants will receive two doses of the vaccine, given one month apart, at different dose levels. The study will observe how the body reacts to the vaccine and how it affects the immune system’s ability to respond to the virus. The study will include adults aged 18 years and older.

Throughout the study, participants will be monitored for any symptoms or side effects after receiving the vaccine. The study will also measure the immune response by looking at specific cells in the blood that help fight infections. This will help researchers understand how well the vaccine works in protecting against . The study is expected to continue for several years to gather comprehensive data on the vaccine’s effectiveness and safety.

]]> Study on COVID-19 Prevention Using Sipavibart and Cilgavimab for Patients with Weakened Immune Systems https://clinicaltrials.eu/trial/study-on-covid-19-prevention-using-sipavibart-and-cilgavimab-for-patients-with-weakened-immune-systems/ Wed, 29 Apr 2026 15:05:34 +0000 https://clinicaltrials.eu/trial/study-on-covid-19-prevention-using-sipavibart-and-cilgavimab-for-patients-with-weakened-immune-systems/ This clinical trial is focused on studying the prevention of COVID-19, a disease caused by the SARS-CoV-2 virus, in people with weakened immune systems. The study will test a new treatment called Sipavibart (also known by its code name AZD3152), which is a type of protein designed to help the body fight off the virus. Another treatment being studied is EVUSHELD, which contains a protein called cilgavimab. Both treatments are given as injections. The study will also use a substance called sodium chloride as a comparison.

The purpose of the study is to evaluate the safety and effectiveness of these treatments in preventing symptoms of COVID-19. Participants will receive either Sipavibart, EVUSHELD, or a placebo. The study will monitor participants over a period of time to see if they develop symptoms of COVID-19 and to assess any side effects from the treatments. The study will also look at how well the treatments work against different variants of the virus.

Participants in the study will be monitored for any side effects and the occurrence of COVID-19 symptoms. The study will also measure the levels of the treatments in the body over time. This research aims to provide valuable information on how these treatments can help protect people with immune system challenges from COVID-19.

]]>